Riociguat for the Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension: A Randomized, Double-Blind, Placebo-Controlled Study (CHEST-1)

doi:10.1378/chest.1462924

Chest

Volume 142, Issue 4, Supplement, October 2012, Page 1023A

https://doi.org/10.1378/chest.1462924 Get rights and content

Section snippets

Abstract

SESSION TYPE: Late-Breaking Abstracts

PRESENTED ON: Tuesday, October 23, 2012 at 04:30 PM - 05:45 PM

PURPOSE: Riociguat is the first member of a novel class of compounds, the soluble guanylate cyclase (sGC) stimulators. With a dual mode of action, it synergizes with endogenous nitric oxide (NO) and also directly stimulates sGC independent of NO availability. Riociguat restores the NO-sGC-cGMP pathway resulting in a significant improvement in pulmonary vascular hemodynamics and an increase in

References (0)

Cited by (0)

View full text

Chest

Signs and Symptoms of Chest Diseases | October 2012Riociguat for the Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension: A Randomized, Double-Blind, Placebo-Controlled Study (CHEST-1)

Section snippets

Abstract

Signs and Symptoms of Chest Diseases | October 2012
Riociguat for the Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension: A Randomized, Double-Blind, Placebo-Controlled Study (CHEST-1)